Skip to content

Oruka Therapeutics, Inc. ORKA Deferred Tax Liabilities, Gross

Deferred Tax Liabilities, Gross at other companies

State Street logo
State StreetSTT
$972M+5.8%
Keysight Technologies logo
Keysight TechnologiesKEYS
$459M+30.0%
MSCI logo
MSCIMSCI
$245.53M+29.4%
Arthur J. Gallagher logo
Arthur J. GallagherAJG
$2.74B+240%
PepsiCo logo
PepsiCoPEP
$4.66B+13.0%
L3Harris Technologies logo
L3Harris TechnologiesLHX
$3.28B-8.9%

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.03B+533%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DeferredIncomeTaxLiabilities.

The official record: Oruka Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s deferred tax liabilities, gross.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s deferred tax liabilities, gross?
Oruka Therapeutics, Inc. (ORKA) reported deferred tax liabilities, gross of $424K in Q4 2025.